Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Division of Developmental and Behavioral Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
J Dev Behav Pediatr. 2022 Aug 1;43(6):311-319. doi: 10.1097/DBP.0000000000001074. Epub 2022 Mar 21.
The objective of this study was to examine the simultaneous impact of patient-related and parent-related factors, medication-related factors, and health care system-related factors on attention-deficit/hyperactivity disorder (ADHD) medication continuity.
Stimulant-naïve children (N = 144, M age = 8 yrs, 71% male) with ADHD completed a methylphenidate (MPH) trial and were followed for 1 year after trial completion and return to community care. Multivariable analysis investigated predictors of (1) having at least 1 filled ADHD prescription after return to community care versus none and (2) having more days covered with medicine after return to community care. Predictors included race; age; sex; income; baseline ADHD symptom severity; MPH trial experience; child and parent mental health conditions; and parent beliefs about ADHD, ADHD medications, and therapeutic alliance.
One hundred twenty-one children (84%) had at least 1 filled ADHD medication prescription (mean = 178 d covered by medication) in the year after return to community care. Multivariable models found that a weaker perceived clinician-family working alliance predicted not filling any ADHD prescriptions. Among those who filled ≥1 prescription, factors linked to fewer days of ADHD medication coverage included child sociodemographic factors (non-White race, older age, being female, and lower income), lower parent beliefs that the child's ADHD affects their lives, and higher parent beliefs that medication is harmful, while child oppositional defiant disorder and parental ADHD predicted having more days of medication coverage.
Child demographic factors, parent beliefs, and medication-related factors are associated with continuation of ADHD medication. These findings may facilitate the development of effective strategies to improve ADHD medication continuity for children from diverse groups.
本研究旨在同时考察患者相关因素、家长相关因素、药物相关因素和医疗保健系统相关因素对注意缺陷多动障碍(ADHD)药物治疗连续性的影响。
144 名(N=144)初治兴奋剂的 ADHD 儿童(平均年龄 8 岁,71%为男性)完成了哌甲酯(MPH)试验,并在试验结束后 1 年返回社区护理时进行了随访。多变量分析考察了以下因素对(1)在返回社区护理后至少有 1 次 ADHD 处方与无 ADHD 处方的预测作用,(2)在返回社区护理后更多天的药物覆盖的预测作用:种族;年龄;性别;收入;基线 ADHD 症状严重程度;MPH 试验经历;儿童和家长的心理健康状况;以及家长对 ADHD、ADHD 药物和治疗联盟的信念。
在返回社区护理后的 1 年内,有 121 名儿童(84%)至少有 1 次 ADHD 药物处方(平均 178 天药物覆盖)。多变量模型发现,感知到的临床医生-家庭工作联盟较弱预示着不会开任何 ADHD 处方。在开了≥1 个 ADHD 药物处方的儿童中,与 ADHD 药物覆盖天数较少相关的因素包括儿童社会人口统计学因素(非白人种族、年龄较大、女性和较低的收入)、家长认为 ADHD 对孩子生活的影响较小的信念,以及家长认为药物有害的信念较高,而儿童对立违抗障碍和父母 ADHD 则预示着有更多的药物覆盖天数。
儿童人口统计学因素、家长信念和药物相关因素与 ADHD 药物的持续使用相关。这些发现可能有助于制定有效的策略,改善来自不同群体的儿童 ADHD 药物的连续性。